Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Int Urogynecol J ; 26(10): 1495-502, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25982786

RESUMO

INTRODUCTION AND HYPOTHESIS: A relationship between urinary incontinence and hypermobility of the urethrovesical junction (UVJ) during pregnancy has been described. The aim of the study was to compare the effects of vaginal delivery (VD) and caesarean section (CS) on UVJ mobility. METHODS: The retrovesical angle (RVA) and the anterior angle between the UVJ and the pubic bone, the pubovesical angle (PVA), were evaluated ultrasonographically in controls and pregnant women during their first pregnancy between 38 and 40 weeks, and then re-evaluated 6 weeks and 6 months after delivery. All patients completed a validated questionnaire (ICIQ-SF). Differences between and within groups were assessed with Student's t test, the chi-squared test for trend, and one-way two-tailed analysis of variance with Scheffé's post-hoc test. The correlation between PVA and RVA was evaluated using the Spearman R correlation. The positive predictive value, negative predictive value, sensitivity and specificity for the prediction of stress urinary incontinence (SUI) symptoms were also determined. RESULTS: Included in the study were 42 controls and 217 pregnant women. PVA at rest, during cough and Valsalva manoeuvre was significantly higher in pregnant women than in controls and in women 6 weeks after VD in comparison with women who had undergone CS. Patients affected by SUI showed a significantly higher PVA. RVA did not differ between subjects affected or not by SUI symptoms. PVA and RVA were not correlated with each other. CONCLUSIONS: PVA and RVA are increased in pregnant women in comparison with controls. In patients undergoing VD, PVA is restored significantly later than in those undergoing CS. The change in RVA after pregnancy and delivery seems to persist longer than the change in PVA.


Assuntos
Período Pós-Parto/fisiologia , Gravidez/fisiologia , Uretra/diagnóstico por imagem , Bexiga Urinária/diagnóstico por imagem , Incontinência Urinária por Estresse/etiologia , Adulto , Estudos de Casos e Controles , Parto Obstétrico/efeitos adversos , Feminino , Humanos , Estudos Longitudinais , Ultrassonografia , Uretra/fisiologia , Bexiga Urinária/fisiologia , Adulto Jovem
2.
Anim Genet ; 45(3): 392-9, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24467435

RESUMO

Appaloosa horses are predisposed to equine recurrent uveitis (ERU), an immune-mediated disease characterized by recurring inflammation of the uveal tract in the eye, which is the leading cause of blindness in horses. Nine genetic markers from the ECA1 region responsible for the spotted coat color of Appaloosa horses, and 13 microsatellites spanning the equine major histocompatibility complex (ELA) on ECA20, were evaluated for association with ERU in a group of 53 Appaloosa ERU cases and 43 healthy Appaloosa controls. Three markers were significantly associated (corrected P-value <0.05): a SNP within intron 11 of the TRPM1 gene on ECA1, an ELA class I microsatellite located near the boundary of the ELA class III and class II regions and an ELA class II microsatellite located in intron 1 of the DRA gene. Association between these three genetic markers and the ERU phenotype was confirmed in a second population of 24 insidious ERU Appaloosa cases and 16 Appaloosa controls. The relative odds of being an ERU case for each allele of these three markers were estimated by fitting a logistic mixed model with each of the associated markers independently and with all three markers simultaneously. The risk model using these markers classified ~80% of ERU cases and 75% of controls in the second population as moderate or high risk, and low risk respectively. Future studies to refine the associations at ECA1 and ELA loci and identify functional variants could uncover alleles conferring susceptibility to ERU in Appaloosa horses.


Assuntos
Doenças dos Cavalos/genética , Uveíte/veterinária , Alelos , Animais , Marcadores Genéticos , Cavalos , Repetições de Microssatélites , Modelos Genéticos , Polimorfismo de Nucleotídeo Único , Fatores de Risco , Uveíte/genética
3.
Biomed Res Int ; 2019: 3726957, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30834263

RESUMO

OBJECTIVES: To evaluate the impact on metabolism, bleeding, and sexual function of Nexplanon, a subdermal implant. STUDY DESIGN: We recruited women (n=101) receiving the Nexplanon implant at two university centers in Italy between 2011 and 2016 into this prospective, observational, multicenter research trial. Participants completed the Interview for Ratings of Sexual Function (IRSF) and the Female Sexual Function Index (FSFI) questionnaires before and 3 and 6 months after the implant was inserted. In addition, all blood parameters were assessed at these visits. All women were given a menstrual diary card and a pictorial blood assessment chart to record daily any vaginal bleeding. RESULTS: The studied metabolic parameters remained in the normal range, showing no alarming modifications: minimal statistical reductions (in aspartate aminotransferase, alanine aminotransferase, total cholesterol, triglycerides, and activated partial thromboplastin time) and increases (in glucose and prothrombin activity) were observed. Changes in IRSF score over 6 months showed a significant increase in pleasure, personal initiative, orgasm, intensity of orgasm, and satisfaction, and a significant decrease in anxiety and discomfort. Mean Body Mass Index decreased, and the weekly frequency of sexual intercourse increased. CONCLUSIONS: Nexplanon showed not only a lower metabolic and bleeding impact, but also important positive effects on sexual function. It expands the range of possibilities for women, 38 and couples, in the modern concepts of sexual and reproductive wellbeing.


Assuntos
Desogestrel/administração & dosagem , Orgasmo/efeitos dos fármacos , Comportamento Sexual/efeitos dos fármacos , Hemorragia Uterina/tratamento farmacológico , Adulto , Alanina Transaminase/sangue , Aspartato Aminotransferases/sangue , Índice de Massa Corporal , Colesterol/sangue , Coito , Anticoncepcionais Femininos , Feminino , Humanos , Itália/epidemiologia , Menstruação/efeitos dos fármacos , Tempo de Tromboplastina Parcial , Satisfação Pessoal , Inquéritos e Questionários , Triglicerídeos/sangue , Hemorragia Uterina/sangue , Hemorragia Uterina/fisiopatologia , Adulto Jovem
4.
Eur J Obstet Gynecol Reprod Biol ; 174: 27-34, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24411952

RESUMO

Besides life-style changes, electrical stimulation or surgery, pharmacological treatment is becoming the first-choice approach in women suffering from lower urinary tract symptoms (LUTS), including urge urinary incontinence (UUI) and overactive bladder (OAB). Several drugs for the treatment of bladder storage and voiding disorders are currently available and, in the near future, novel compounds with higher specificity for the lower urinary tract receptors will be accessible. This will bring optimization of therapy, reducing side effects and increasing compliance, especially in patients with comorbidities and in women. The purpose of this paper is to give an overview on the pharmacotherapy of two common inter-correlated urological conditions, UUI and OAB. The study was conducted by analyzing and comparing the data of the recent international literature on this topic. Advances in the discovery of pharmacological options have dramatically improved the quality of life of patients affected by incontinence, but further studies are needed to increase the effectiveness and safety of the therapies used in this field.


Assuntos
Bexiga Urinária Hiperativa/tratamento farmacológico , Incontinência Urinária de Urgência/tratamento farmacológico , Antagonistas Adrenérgicos alfa/efeitos adversos , Antagonistas Adrenérgicos alfa/uso terapêutico , Agonistas Adrenérgicos beta/efeitos adversos , Agonistas Adrenérgicos beta/uso terapêutico , Toxinas Botulínicas Tipo A/efeitos adversos , Toxinas Botulínicas Tipo A/uso terapêutico , Estrogênios/efeitos adversos , Estrogênios/uso terapêutico , Feminino , Humanos , Antagonistas Muscarínicos/efeitos adversos , Antagonistas Muscarínicos/uso terapêutico , Inibidores de Fosfodiesterase/efeitos adversos , Inibidores de Fosfodiesterase/uso terapêutico , Moduladores Seletivos de Receptor Estrogênico/efeitos adversos , Moduladores Seletivos de Receptor Estrogênico/uso terapêutico , Canais de Cátion TRPV/agonistas
5.
Female Pelvic Med Reconstr Surg ; 20(4): 185-202, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24978084

RESUMO

We present an overview of the current pharmacological treatment of urinary incontinence (UI) in women, according to the latest evidence available. After a brief description of the lower urinary tract receptors and mediators (detrusor, bladder neck, and urethra), the potential sites of pharmacological manipulation in the treatment of UI are discussed. Each class of drug used to treat UI has been evaluated, taking into account published rate of effectiveness, different doses, and way of administration. The prevalence of the most common adverse effects and overall compliance had also been pointed out, with cost evaluation after 1 month of treatment for each class of drug. Moreover, we describe those newer agents whose efficacy and safety need to be further investigated. We stress the importance of a better understanding of the causes and pathophysiology of UI to ensure newer and safer treatments for such a debilitating condition.


Assuntos
Incontinência Urinária/tratamento farmacológico , Fenômenos Fisiológicos do Sistema Urinário , Sistema Urinário/efeitos dos fármacos , Agentes Urológicos , Antagonistas Adrenérgicos alfa/uso terapêutico , Antidepressivos Tricíclicos/uso terapêutico , Antidiuréticos/uso terapêutico , Estrogênios/uso terapêutico , Feminino , Humanos , Antagonistas Muscarínicos/farmacologia , Antagonistas Muscarínicos/uso terapêutico , Neurotoxinas/uso terapêutico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Resultado do Tratamento , Agentes Urológicos/farmacologia , Agentes Urológicos/uso terapêutico
6.
Case Rep Obstet Gynecol ; 2012: 190167, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22919522

RESUMO

A 29-year-old Para 2 was admitted to the emergency department with increasing lower abdominal pain. The patient had undergone an uncomplicated elective repeat caesarean section 7 days before being admitted to the emergency department. An emergency laparotomy revealed a uterus didelphys with a torsion of one of the uteri.

7.
J Free Radic Biol Med ; 2(3): 189-92, 1986.
Artigo em Inglês | MEDLINE | ID: mdl-3033047

RESUMO

The iron chelator, 1,10-phenanthroline (Phen), which inhibits hydroxyl radical formation, was tested in vitro and in vivo against alloxan and streptozotocin (STZ) cytotoxicity. Phen injection reduced the severity of alloxan-induced diabetes in rats and attenuated alloxan-induced toxicity in human fibroblasts (VA 13 line) in culture. These protective effects were not observed against STZ toxic action. These results are consistent with the hypothesis that hydroxyl radicals, generated via an iron-catalyzed reaction, induce the alloxan but not the STZ diabetogenic effects.


Assuntos
Aloxano/toxicidade , Diabetes Mellitus Experimental/prevenção & controle , Quelantes de Ferro/farmacologia , Fenantrolinas/farmacologia , Estreptozocina/toxicidade , Animais , Células Cultivadas , Hidróxidos , Radical Hidroxila , Masculino , Compostos de Metilureia/farmacologia , Ratos , Ratos Endogâmicos
8.
Andrologia ; 33(2): 75-7, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11350370

RESUMO

The objective of the study was to compare the water test and the hypoosmotic test (HOS) in the assessment of the human sperm membrane. A total of 686 semen samples from human male donors were subjected to water and HOS tests after routine semen evaluation. The mean percentage of swollen spermatozoa was 71.8 +/- 9.6% in the HOS test and 67.8 +/- 9.4% for the water test; these values were not statistically different. The correlation of coefficients between the water test and the HOS test was highly significant whether the values for the HOS test were higher or lower than 60% (P < 0.001). A poor correlation was obtained when the two tests were compared for sperm counts either higher or lower than 20 x 6 ml-1 and when the results for both tests were compared with the percentage of eosin-Y staining spermatozoa. A poor correlation was also obtained when the results of each test were compared with eosin-Y staining spermatozoa in normal and abnormal semen samples. The coefficient of regression between the two tests showed a high correlation (P < 0.001). In conclusion, even though a high correlation between the HOS test and water test was observed in this study, it is not possible to recommend assessment of sperm membrane integrity using the water test and the consequent replacement of the HOS test in routine practice. Further studies are necessary to establish the best test for sperm vitality.


Assuntos
Membrana Celular/fisiologia , Soluções Hipotônicas , Espermatozoides/ultraestrutura , Água , Citratos , Corantes Fluorescentes , Frutose , Humanos , Masculino , Citrato de Sódio
9.
Andrologia ; 25(6): 351-3, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8279708

RESUMO

Fifty-nine men who requested vasectomy and 43 infertile patients had a semen analysis performed prior to surgery or during evaluation. A hypo-osmotic swelling test (HOS) and a new 'Water test' were performed simultaneously, in order to assess correlation between these two procedures. Our results showed that values obtained with the 'Water test' were significantly higher than those obtained with the HOS test (P < 0.001). These findings suggest that it is necessary to determine normal values for this new test before introducing it in the routine semen analysis.


Assuntos
Membrana Celular/fisiologia , Soluções Hipotônicas , Espermatozoides/ultraestrutura , Água , Citratos , Ácido Cítrico , Frutose , Humanos , Masculino , Pressão Osmótica , Espermatozoides/fisiologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa